Sage Therapeutics Inc (SAGE)
12.12
+0.07
(+0.58%)
USD |
NASDAQ |
May 22, 16:00
12.12
0.00 (0.00%)
After-Hours: 20:00
Sage Therapeutics Cash from Investing (Quarterly): 139.44M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 139.44M |
December 31, 2023 | 42.06M |
September 30, 2023 | 160.39M |
June 30, 2023 | 45.59M |
March 31, 2023 | 194.87M |
December 31, 2022 | 89.78M |
September 30, 2022 | 110.95M |
June 30, 2022 | 134.26M |
March 31, 2022 | -9.558M |
December 31, 2021 | -30.26M |
September 30, 2021 | -24.98M |
June 30, 2021 | -288.39M |
March 31, 2021 | -658.82M |
December 31, 2020 | 45.52M |
September 30, 2020 | 13.51M |
June 30, 2020 | 177.38M |
March 31, 2020 | 206.27M |
December 31, 2019 | -17.92M |
September 30, 2019 | 207.78M |
June 30, 2019 | -58.11M |
March 31, 2019 | -274.91M |
December 31, 2018 | 38.42M |
September 30, 2018 | 0.052M |
Date | Value |
---|---|
June 30, 2018 | -238.13M |
March 31, 2018 | -312.80M |
December 31, 2017 | -104.60M |
September 30, 2017 | 43.87M |
June 30, 2017 | 44.59M |
March 31, 2017 | 31.60M |
December 31, 2016 | -117.94M |
September 30, 2016 | -27.72M |
June 30, 2016 | -84.02M |
March 31, 2016 | -0.341M |
December 31, 2015 | -0.038M |
September 30, 2015 | 0.021M |
June 30, 2015 | -0.071M |
March 31, 2015 | -0.11M |
December 31, 2014 | -0.045M |
September 30, 2014 | -0.078M |
June 30, 2014 | -0.002M |
March 31, 2014 | -0.003M |
December 31, 2013 | 0.00 |
September 30, 2013 | 0.00 |
June 30, 2013 | 0.00 |
March 31, 2013 | -0.003M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-658.82M
Minimum
Mar 2021
207.78M
Maximum
Sep 2019
23.99M
Average
45.56M
Median
Cash from Investing (Quarterly) Benchmarks
Biogen Inc | -66.00M |
Vanda Pharmaceuticals Inc | -18.22M |
Ligand Pharmaceuticals Inc | -3.775M |
ADMA Biologics Inc | -2.362M |
Axsome Therapeutics Inc | -0.098M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -37.83M |
Cash from Financing (Quarterly) | 1.557M |
Free Cash Flow | -424.74M |
Free Cash Flow Per Share (Quarterly) | -0.6291 |
Free Cash Flow to Equity (Quarterly) | -37.83M |
Free Cash Flow Yield | -58.45% |